News

Filter

AbbVie to pay $50 million to expand GLPG0634 deal with Galapagos to Crohn's disease

17-05-2013

US drugmaker AbbVie (NYSE: ABBV) says it is extending its deal with Belgium-based Galapagos (Euronext:…

AbbVieAnti-Arthritics/RheumaticsGalapagosGLPG0634Inflammatory diseasesLicensingPharmaceuticalResearch

GSK exercises option for Galapagos drug candidates

21-02-2012

Belgium-based Galapagos NV (Euronext: GLPG) says that its partner, UK pharma giant GlaxoSmithKline (LSE:…

Anti-Arthritics/RheumaticsBiotechnologyGalapagosGlaxoSmithKlineInflammatory diseasesLicensingPharmaceuticalResearch

COMPANY SPOTLIGHT

Menarini

Back to top